Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (XETRA:BRM) — Drug Manufacturers - General. Numărul de burse pe care se tranzacționează acțiunile companiei: 6. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.
Despre Companie
- Site Web
- bms.com
- Relații cu Investitorii
- bms.com/investors.html
- Sector
- Healthcare · Drug Manufacturers - General
- Sediu Central
- PRINCETON, United States
- Director General
- Christopher S. Boerner
- Angajați
- 32 500
- Fondată
- 1989
- Acțiuni în Circulație
- 2.04 mld. la 2026-07-22
- Free Float
- 2.04 mld.
- Capitalizare de Piață
- 128.41 mld. USD
- Insideri
- 0.1%
- Investitori Instituționali
- 84.87%
- Industrie (SIC)
- Pharmaceutical Preparations
- Formă Juridică
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- Rata de Distribuire
- 54.9%
- FCF
- 11.4 mld. USD45%
- Datorie
- 43.9 mld. USD3.1 ani FCF
- Vechimea Dividendelor
- 54 ani
- Câștiguri, FCF și dividende plătite — pentru cele 12 luni până la 30.06.2026 (cel mai recent raport al companiei).
Descriere
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Burse și Simboluri
| Bursă | Simbol | Monedă | Preț | Tip |
|---|---|---|---|---|
| US USA Stocks | BMY principală | USD | 59.58 -0.20% | acțiuni ordinare |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | acțiuni ordinare |
| MI Borsa Italiana (Milan) | 1BMY secundară | EUR | 53.13 +0.28% | acțiuni ordinare |
| MX Mexican Stock Exchange | BMY secundară | MXN | 1 088.5 +1.73% | acțiuni ordinare |
| VI Vienna Stock Exchange | BMYS secundară | EUR | 52.98 +0.34% | acțiuni ordinare |
| XETRA Xetra | BRM secundară | EUR | 53.04 +0.89% | acțiuni ordinare |
Dividende
Bristol-Myers Squibb Company (BMYS) plătește dividende trimestrial. Pe an (12 luni până la și inclusiv cea mai recentă plată anunțată): 0.562 EUR pe acțiune (plăți: 1). Aceasta reprezintă aproximativ 1.06% din prețul actual al acțiunilor. Pe baza istoricului plăților, următoarea dată ex-dividend este așteptată în jurul datei de 01.01.2027. Istoric neîntrerupt al dividendelor: 54 ani.
| Data Ex | Plată | Sumă | % | Tip | Simbol |
|---|---|---|---|---|---|
| 2026-10-02 | — | 0.5620 EUR | 1.1/4.2 % | — | VI:BMYS |
| 2026-07-02 | — | 0.5540 EUR | 1.0/4.2 % | trimestrial | XETRA:BRM |
| 2026-04-02 | — | 0.5540 EUR | 1.0/4.1 % | trimestrial | XETRA:BRM |
| 2026-01-02 | — | 0.5540 EUR | 1.0/4.1 % | trimestrial | XETRA:BRM |
| 2025-10-03 | — | 0.5452 EUR | 1.0/4.1 % | trimestrial | XETRA:BRM |
| 2025-07-03 | — | 0.5452 EUR | 1.0/4.1 % | trimestrial | XETRA:BRM |
| 2025-04-04 | — | 0.5452 EUR | 1.0/4.0 % | trimestrial | XETRA:BRM |
| 2025-01-03 | — | 0.5452 EUR | 1.0/4.0 % | trimestrial | XETRA:BRM |
| 2024-10-04 | — | 0.5276 EUR | 1.0/4.0 % | trimestrial | XETRA:BRM |
| 2024-07-05 | — | 0.5276 EUR | 1.0/3.9 % | trimestrial | XETRA:BRM |
| 2024-04-04 | — | 0.5276 EUR | 1.0/3.9 % | trimestrial | XETRA:BRM |
| 2024-01-04 | — | 0.5276 EUR | 1.0/3.8 % | trimestrial | XETRA:BRM |
| 2023-10-05 | — | 0.5013 EUR | 0.9/3.8 % | trimestrial | XETRA:BRM |
| 2023-07-06 | — | 0.5013 EUR | 0.9/3.7 % | trimestrial | XETRA:BRM |
| 2023-04-06 | — | 0.5013 EUR | 0.9/3.7 % | trimestrial | XETRA:BRM |
| 2023-01-05 | — | 0.5013 EUR | 0.9/3.6 % | trimestrial | XETRA:BRM |
| 2022-10-06 | — | 0.4749 EUR | 0.9/3.6 % | trimestrial | XETRA:BRM |
| 2022-06-30 | — | 0.4749 EUR | 0.9/2.7 % | trimestrial | XETRA:BRM |
| 2022-03-31 | — | 0.4749 EUR | 0.9/1.8 % | trimestrial | XETRA:BRM |
| 2022-01-06 | — | 0.4749 EUR | 0.9/0.9 % | trimestrial | XETRA:BRM |
Știri din Această Săptămână
Comunicate de presă de pe site-ul investitorilor companiei, actualizate zilnic. Linkurile duc către site-ul companiei. Titlurile sunt în limba originală, ca pe site-ul companiei.
Cei Mai Mari Acționari
| Deținător | Participație | Acțiuni | Data Raportului |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 mil. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 mil. | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 mil. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 mil. | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 mil. | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 mil. | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 mil. | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 mil. | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 mil. | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 mil. | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 mil. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 mil. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 mil. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 mil. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 mil. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 mil. | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 mil. | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 mil. | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
